These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 22248871)

  • 21. Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome.
    Zappe DH; Sowers JR; Hsueh WA; Haffner SM; Deedwania PC; Fonseca VA; Keeling L; Sica DA
    J Clin Hypertens (Greenwich); 2008 Dec; 10(12):894-903. PubMed ID: 19120715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial.
    Calhoun DA; Lacourcière Y; Chiang YT; Glazer RD
    Hypertension; 2009 Jul; 54(1):32-9. PubMed ID: 19470877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study.
    Allemann Y; Fraile B; Lambert M; Barbier M; Ferber P; Izzo JL
    J Clin Hypertens (Greenwich); 2008 Mar; 10(3):185-94. PubMed ID: 18326958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension.
    Frampton JE; Scott LJ
    Am J Cardiovasc Drugs; 2009; 9(5):309-30. PubMed ID: 19791840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 24-hour ambulatory blood-pressure effects of valsartan and hydrochlorothiazide combinations compared with amlodipine in hypertensive patients at increased cardiovascular risk: a VAST sub-study.
    Ruilope LM; Heintz D; Brandão AA; Stolt P; Kandra A; Santonastaso M; Khder Y
    Blood Press Monit; 2005 Apr; 10(2):85-91. PubMed ID: 15812256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update.
    Destro M; Cagnoni F; D'Ospina A; Ricci AR; Demichele E; Peros E; Zaninelli A; Preti P
    Vasc Health Risk Manag; 2010 Apr; 6():253-60. PubMed ID: 20407632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Achieving BP goals with valsartan and HCTZ alone and in combination: pooled analysis of two randomized, double-blind, placebo-controlled studies.
    Nash DT; Crikelair N; Zappe D
    Curr Med Res Opin; 2008 Sep; 24(9):2617-26. PubMed ID: 18687165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension.
    White WB; Punzi HA; Murwin D; Koval SE; Davidai G; Neutel JM
    J Clin Hypertens (Greenwich); 2006 Sep; 8(9):626-33. PubMed ID: 16957424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.
    Calhoun DA; Glazer RD; Pettyjohn FS; Coenen PD; Zhao Y; Grosso A
    Curr Med Res Opin; 2008 Aug; 24(8):2303-11. PubMed ID: 18593517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXALT) study.
    Wright RF; Duprez D; Purkayastha D; Samuel R; Ferdinand KC
    J Clin Hypertens (Greenwich); 2011 Aug; 13(8):588-97. PubMed ID: 21806769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale and design of the Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) trial.
    Odili AN; Richart T; Thijs L; Kingue S; Boombhi HJ; Lemogoum D; Kaptue J; Kamdem MK; Mipinda JB; Omotoso BA; Kolo PM; Aderibigbe A; Ulasi II; Anisiuba BC; Ijoma CK; Ba SA; Ndiaye MB; Staessen JA; M'buyamba-Kabangu JR;
    Blood Press; 2011 Oct; 20(5):256-66. PubMed ID: 21495829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria.
    Fogari R; Derosa G; Zoppi A; Lazzari P; D'Angelo A; Mugellini A
    Expert Opin Pharmacother; 2014 Mar; 15(4):453-9. PubMed ID: 24410484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients.
    Jordan J; Engeli S; Boschmann M; Weidinger G; Luft FC; Sharma AM; Kreuzberg U
    J Hypertens; 2005 Dec; 23(12):2313-8. PubMed ID: 16269974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake.
    Weir MR; Smith DH; Neutel JM; Bedigian MP
    Am J Hypertens; 2001 Jul; 14(7 Pt 1):665-71. PubMed ID: 11465651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial.
    White WB; Calhoun DA; Samuel R; Taylor AA; Zappe DH; Purkayastha D
    J Clin Hypertens (Greenwich); 2008 Jun; 10(6):450-8. PubMed ID: 18550935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
    Karalliedde J; Maltese G; Hill B; Viberti G; Gnudi L
    Clin J Am Soc Nephrol; 2013 Nov; 8(11):1899-905. PubMed ID: 23929932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension.
    Wellington K; Faulds DM
    Drugs; 2002; 62(13):1983-2005. PubMed ID: 12215069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients.
    Bakris GL; Smith DH; Giles TD; White WB; Davidai G; Weber MA
    J Clin Hypertens (Greenwich); 2005 Oct; 7(10):587-95; quiz 596-7. PubMed ID: 16227761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
    Julius S; Kjeldsen SE; Weber M; Brunner HR; Ekman S; Hansson L; Hua T; Laragh J; McInnes GT; Mitchell L; Plat F; Schork A; Smith B; Zanchetti A;
    Lancet; 2004 Jun; 363(9426):2022-31. PubMed ID: 15207952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of CPAP on "vascular" risk factors in patients with obstructive sleep apnea and arterial hypertension.
    Litvin AY; Sukmarova ZN; Elfimova EM; Aksenova AV; Galitsin PV; Rogoza AN; Chazova IE
    Vasc Health Risk Manag; 2013; 9():229-35. PubMed ID: 23690688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.